João Marcello de Araujo-Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
João Marcello de Araujo-Neto has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Amelio Fernando Godoy-Matos
Sociedade Brasileira de Diabetes (SBD), São Paulo, Brazil
3 shared publications - Cynthia Melissa Valerio
Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO), São Paulo, Brazil
3 shared publications - Wellington Santana Silva Júnior
Universidade Federal do Maranhão, Brasil
3 shared publications - Marcello Casaccia Bertoluci
Universidade Federal do Rio Grande do Sul, Brasil
2 shared publications A. M. C. F. Bottino
Pathology Department, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
1 shared publication- Andrei Carvalho Sposito
Department of Internal Medicine, School of Medical Sciences, State University of Campinas, Campinas, Brazil
1 shared publication
Latest Publications
- Open Access
- 16 June 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-17
CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease
Metabolic Syndrome—a constellation of insulin resistance, cardiovascular risk factors as hyperglycemia, hypertension, and dyslipidemia, and systemic metabolic dysfunction—may be driven by dysregulation of adipose tissue, which manifests as adiposopathy (pathogenic adipose tissue expansion or maldistribution), ectopic fat deposition (in the liver, muscle, pancreas, and cardiorenal systems), and altered secretion of adipokines/hepatokines. Weight gain, obesity, and/or unfavorable fat distribution create a scenario wherein the type, size, location, secretions, or even scarcity of adipocytes drive pathophysiological mechanisms leading to hepatic steatosis and steatohepatitis, type 2 diabetes, and heart and kidney disease. While recent frameworks, such as cardiovascular-kidney-metabolic syndrome, emphasize holistic staging, the central role of metabolic dysfunction-associated steatotic liver disease (MASLD) in multisystem morbidity remains underrecognized. This narrative review synthesizes evidence linking MASLD and diabetes to cardiovascular and kidney diseases through shared pathways of adiposopathy, ectopic lipid accumulation, and dysregulated adipokine/hepatokine signaling. We propose CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome), an expanded pathophysiological model that unifies these interactions into four progressive stages: (1) weight gain and dysfunctional adipose tissue; (2) metabolic risk factors and markers of risk; (3) cardiometabolic diseases and chronic kidney disease; and (4) advanced cardio-renal-liver-metabolic disease. By integrating MASLD as a pivotal component, CARDIAL-MS reframes metabolic syndrome as a continuum of interconnected organ injuries rather than isolated risk factors. CARDIAL-MS provides a staging model to identify patients at critical transition points—from reversible metabolic disturbances to irreversible organ damage. This model emphasizes early interventions targeting adipose tissue health and ectopic fat deposition to mitigate the progression of metabolic cardiorenal diseases. By recognizing the syndromic nature of these conditions, CARDIAL-MS offers clinicians an actionable paradigm for risk stratification, timely diagnosis, and personalized prevention strategies.
- 16 June 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-17
Open AccessCARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease
Metabolic Syndrome—a constellation of insulin resistance, cardiovascular risk factors as hyperglycemia, hypertension, and dyslipidemia, and systemic metabolic dysfunction—may be driven by dysregulation of adipose tissue, which manifests as adiposopathy (pathogenic adipose tissue expansion or maldistribution), ectopic fat deposition (in the liver, muscle, pancreas, and cardiorenal systems), and altered secretion of adipokines/hepatokines. Weight gain, obesity, and/or unfavorable fat distribution create a scenario wherein the type, size, location, secretions, or even scarcity of adipocytes drive pathophysiological mechanisms leading to hepatic steatosis and steatohepatitis, type 2 diabetes, and heart and kidney disease. While recent frameworks, such as cardiovascular-kidney-metabolic syndrome, emphasize holistic staging, the central role of metabolic dysfunction-associated steatotic liver disease (MASLD) in multisystem morbidity remains underrecognized. This narrative review synthesizes evidence linking MASLD and diabetes to cardiovascular and kidney diseases through shared pathways of adiposopathy, ectopic lipid accumulation, and dysregulated adipokine/hepatokine signaling. We propose CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome), an expanded pathophysiological model that unifies these interactions into four progressive stages: (1) weight gain and dysfunctional adipose tissue; (2) metabolic risk factors and markers of risk; (3) cardiometabolic diseases and chronic kidney disease; and (4) advanced cardio-renal-liver-metabolic disease. By integrating MASLD as a pivotal component, CARDIAL-MS reframes metabolic syndrome as a continuum of interconnected organ injuries rather than isolated risk factors. CARDIAL-MS provides a staging model to identify patients at critical transition points—from reversible metabolic disturbances to irreversible organ damage. This model emphasizes early interventions targeting adipose tissue health and ectopic fat deposition to mitigate the progression of metabolic cardiorenal diseases. By recognizing the syndromic nature of these conditions, CARDIAL-MS offers clinicians an actionable paradigm for risk stratification, timely diagnosis, and personalized prevention strategies.
- Open Access
- 28 February 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-2
Correction: 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction‑associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
- 28 February 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-2
Open AccessCorrection: 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction‑associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
- Open Access
- 19 January 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-15
2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease affecting 30% of the world’s population and is often associated with metabolic disorders such as metabolic syndrome, type 2 diabetes (T2D), and cardiovascular disease. This review is an update of the Brazilian Diabetes Society (Sociedade Brasileira de Diabetes [SBD]) evidence-based guideline for the management of MASLD in clinical practice. Methods: The methodology was published previously and was defined by the internal institutional steering committee. The SBD Metabolic Syndrome and Prediabetes Department drafted the manuscript, selecting key clinical questions for a narrative review using MEDLINE via PubMed with the MeSH terms [diabetes] and [fatty liver]. The best available evidence was reviewed, including randomized clinical trials (RCTs), meta-analyses, and high-quality observational studies related to MASLD. Results and conclusions: The SBD Metabolic Syndrome and Prediabetes Department formulated 9 recommendations for the management of MASLD in people with prediabetes or T2D. Screening for the risk of advanced fibrosis associated with MASLD is recommended in all adults with prediabetes or T2D. Lifestyle modification (LSM) focusing on a reduction in body weight of at least 5% is recommended as the first choice for these patients. In situations where LSMs are insufficient to achieve weight loss, the use of anti-obesity medications is recommended for those with a body mass index (BMI) ≥ 27 kg/m2. Pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1RA) monotherapy are the first-line pharmacological treatments for steatohepatitis in people with T2D, and sodium–glucose cotransporter-2 (SGLT2) inhibitors may be considered in this context. The combination of these agents may be considered in the treatment of steatohepatitis and/or fibrosis, and bariatric surgery should be considered in patients with a BMI ≥ 35 kg/m2, in which the combination of LSM and pharmacotherapy has not been shown to be effective in improving MASLD.
- 19 January 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-15
Open Access2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease affecting 30% of the world’s population and is often associated with metabolic disorders such as metabolic syndrome, type 2 diabetes (T2D), and cardiovascular disease. This review is an update of the Brazilian Diabetes Society (Sociedade Brasileira de Diabetes [SBD]) evidence-based guideline for the management of MASLD in clinical practice. Methods: The methodology was published previously and was defined by the internal institutional steering committee. The SBD Metabolic Syndrome and Prediabetes Department drafted the manuscript, selecting key clinical questions for a narrative review using MEDLINE via PubMed with the MeSH terms [diabetes] and [fatty liver]. The best available evidence was reviewed, including randomized clinical trials (RCTs), meta-analyses, and high-quality observational studies related to MASLD. Results and conclusions: The SBD Metabolic Syndrome and Prediabetes Department formulated 9 recommendations for the management of MASLD in people with prediabetes or T2D. Screening for the risk of advanced fibrosis associated with MASLD is recommended in all adults with prediabetes or T2D. Lifestyle modification (LSM) focusing on a reduction in body weight of at least 5% is recommended as the first choice for these patients. In situations where LSMs are insufficient to achieve weight loss, the use of anti-obesity medications is recommended for those with a body mass index (BMI) ≥ 27 kg/m2. Pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1RA) monotherapy are the first-line pharmacological treatments for steatohepatitis in people with T2D, and sodium–glucose cotransporter-2 (SGLT2) inhibitors may be considered in this context. The combination of these agents may be considered in the treatment of steatohepatitis and/or fibrosis, and bariatric surgery should be considered in patients with a BMI ≥ 35 kg/m2, in which the combination of LSM and pharmacotherapy has not been shown to be effective in improving MASLD.
- 1 February 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 294 (2) , 483-484
Shear-Wave Dispersion Slope: Do We Have the Tool for Detecting Necroinflammation?
- 1 February 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 294 (2) , 483-484
Shear-Wave Dispersion Slope: Do We Have the Tool for Detecting Necroinflammation?
- 1 November 2017
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 25 (3) , 254-261
Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C
Summary: Chronic infection with the hepatitis C virus induces liver fibrosis, but it is unknown why some patients progress to advanced fibrosis while others remain with mild disease. Recently, an inverse association between serum levels of dehydroepiandrosterone sulphate (DHEA‐S) and liver fibrosis in patients with nonalcoholic fatty liver disease was described, and it was postulated that dehydroepiandrosterone (DHEA) has antifibrotic effects. Our aim was to compare serumDHEA‐S levels with liver fibrosis in hepatitis C patients. We collected serum samples from hepatitis C patients at the same day they underwent a liver biopsy. S‐DHEAwas compared to different stages of fibrosis. Binary logistic regression models were applied to evaluate independent variables associated to fibrosis. We included 287 patients (43.9% male). According to fibrosis stages 0, 1, 2, 3 and 4, median serumDHEA‐S levels were 103 (26‐462), 73 (5‐391), 46 (4‐425), 35 (6‐292) and 28 (2‐115) μg/dL, respectively (P < .001). Median serumDHEA‐S levels were 74 (5‐462) vs 36 (2‐425) μg/dLfor mild (F0‐1) vs significant (F2‐4) fibrosis, respectively (P < .001). Median serumDHEA‐S levels were 64 (4‐462) vs 31 (2‐292) μg/dLfor non advanced (F0‐2) vs advanced fibrosis (F3‐4), respectively (P < .001). The same association was found when the subgroup ofHCVpatients with and without steatosis or steatohepatitis was analysed. The association between lowerDHEA‐S levels and advanced fibrosis was independent of age, gender, diabetes mellitus, obesity and steatosis. Lower circulatingDHEA‐S levels are associated with more advanced stages of liver fibrosis in hepatitis C patients.
- 1 November 2017
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 25 (3) , 254-261
Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C
Summary: Chronic infection with the hepatitis C virus induces liver fibrosis, but it is unknown why some patients progress to advanced fibrosis while others remain with mild disease. Recently, an inverse association between serum levels of dehydroepiandrosterone sulphate (DHEA‐S) and liver fibrosis in patients with nonalcoholic fatty liver disease was described, and it was postulated that dehydroepiandrosterone (DHEA) has antifibrotic effects. Our aim was to compare serumDHEA‐S levels with liver fibrosis in hepatitis C patients. We collected serum samples from hepatitis C patients at the same day they underwent a liver biopsy. S‐DHEAwas compared to different stages of fibrosis. Binary logistic regression models were applied to evaluate independent variables associated to fibrosis. We included 287 patients (43.9% male). According to fibrosis stages 0, 1, 2, 3 and 4, median serumDHEA‐S levels were 103 (26‐462), 73 (5‐391), 46 (4‐425), 35 (6‐292) and 28 (2‐115) μg/dL, respectively (P < .001). Median serumDHEA‐S levels were 74 (5‐462) vs 36 (2‐425) μg/dLfor mild (F0‐1) vs significant (F2‐4) fibrosis, respectively (P < .001). Median serumDHEA‐S levels were 64 (4‐462) vs 31 (2‐292) μg/dLfor non advanced (F0‐2) vs advanced fibrosis (F3‐4), respectively (P < .001). The same association was found when the subgroup ofHCVpatients with and without steatosis or steatohepatitis was analysed. The association between lowerDHEA‐S levels and advanced fibrosis was independent of age, gender, diabetes mellitus, obesity and steatosis. Lower circulatingDHEA‐S levels are associated with more advanced stages of liver fibrosis in hepatitis C patients.